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Immune system regulation is of paramount importance to host survival. In settings of autoimmunity and
alloimmunity, control is lost, resulting in injury to vital organs and tissues. Naturally occurring, thymic-derived
T regulatory (Treg) cells that express CD4, CD25, and the forkhead box protein 3 (FoxP3) are potent suppres-
sors of these adverse immune responses. Preclinical studies have shown that either freshly isolated or ex
vivo expanded Treg cells can prevent both local and systemic organ and tissue destruction. Although prom-
ising, human Treg cell infusion therapy has heretofore been difficult to implement in the clinic, and relatively
few clinical trials have been initiated. This reviewwill focus on the preclinical models that provide the rationale
for current trials and it will address both the challenges and opportunities in human Treg cell therapy.Introduction
The immunesystemservesasabarrier against foreignpathogens
and abnormal cell growth. To prevent excessive or indiscriminate
immune responses that might compromise survival of the
organism, several nonredundant regulatory mechanisms exist
to maintain this delicate balance. The focus of this review stems
from the seminal work of Sakaguchi et al. that report the transfer
of CD25+-depleted CD4+ T cells into nude mice resulted in auto-
immunedisease (Sakaguchi et al., 1995). Thediseasecoursewas
reversed by adding CD4+CD25+ T cells (now termed regulatory T
[Treg] cells). The importance of Treg cells in immune regulation
has been well established in mice and humans. Although the
therapeutic potential of Treg cells was envisioned decades ago
(Gershon, 1975), clinical implementation of their potent immune
regulatory activity has proven challenging. Like conventional T
(Tconv) cells, Treg cells need T cell receptor (TCR) triggering
and costimulation to become fully active. Although some costi-
mulatory pathways may differentially regulate Treg cells and
Tconv cells (Riley and June, 2005), no single pathway is known
to regulate one cell type exclusively. Thus, in vivo administration
of agents that augment Treg cell activitymayalso augment Tconv
cell activity. Thispointwasmostdramatically illustrated inaphase
I clinical trial testing TGN1412, a superagonistic CD28 antibody
(Ab) (Suntharalingam et al., 2006). Preclinical data in animal
models demonstrated that this Ab preferentially activated Treg
cells, and it was thus postulated that TGN1412 could restore
tolerance and enable transplants (Beyersdorf et al., 2005; Lin
and Hunig, 2003). Unfortunately, when seemingly low Ab doses
were delivered to six healthy adults, a massive cytokine storm
ensued, and only prompt and intensive medical intervention
prevented deaths (Suntharalingam et al., 2006). The precise
reasons why these adverse events were not observed in rodent
and nonhuman primate models are not known, but this trial
underscores the danger of injecting agents designed tomodulate
T cell activity in vivo without being able to selectively target
specific T cell subsets.656 Immunity 30, May 22, 2009 ª2009 Elsevier Inc.Adoptive Treg cell therapy is an attractive alternative to
harness the immune suppressive activity of Treg cells (June
and Blazar, 2006). In this approach, Treg cells are isolated
from a patient, enriched, expanded ex vivo, and reinfused. This
approach is advantageous because the expanded product can
be analyzed phenotypically and functionally prior to infusion,
providing another level of safety. Furthermore, cell dosage can
be tightly controlled. Despite these advantages, adoptive Treg
cell therapy is just now being tested in the clinic. This review
will evaluate the rationale for the clinical use of ex vivo expanded
Treg cells and it will emphasize the difficulties, as well as the
opportunities, encountered in transitioning from the bench to
the bedside.
Overview of Autoimmune
and Alloimmune Immune Regulation
Autoimmunity can be defined as the loss of self-tolerance. It can
arise from genetic lesions, molecular mimicry, or environmental
stress that overrides the immune system’s safeguards against
self-attack (Christen and Herrath, 2004). Once these protective
measures are overcome, the self immune response shares
many features with the non-self immune response, including
MHC-restricted antigen specificity and immune memory gener-
ation.
Autoimmune disease can be directly caused by Treg cell
dysfunction. The clearest example is immune dysregulation,
polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome, in
which loss-of-function mutations in the FoxP3 gene lead to
severe autoimmunity. However, there are many instances in
which the role of Treg cells in autoimmunity is unclear. For
example, CTLA-4 polymorphisms are associated with autoim-
munity (Scalapino and Daikh, 2008). This association was initially
attributed to a lowered threshold for Tconv cell activation conse-
quent to diminished Treg cell CTLA-4 expression, resulting in
greater activation of self-reactive T cells (Egen et al., 2002).
However, recent studies have indicated that CTLA-4 is also
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Borja et al., 2008; Wing et al., 2008). Obviously, these scenarios
are not mutually exclusive. Nonetheless, the rationale to adop-
tively transfer autologous Treg cells to treat autoimmune disease
associated with the loss of CTLA-4 activity would be stronger if
Treg cell function is reasonably preserved and autoimmunity is
due to higher numbers of autoreactive T cells. Here, the addition
of functional Treg cells may reset the proper balance between
tolerance and immunity. On the other hand, if CTLA-4 activity
is required for Treg cell effector functions, then the rationale of
infusing additional non-fully functional Treg cells is not so clear.
The precise contribution of reduced Treg cell numbers and
reduced Treg cell activity to autoimmunity is an important unre-
solved issue. Although reduced numbers of Treg cells have been
observed in type I diabetes (T1D) patients (Kukreja et al., 2002),
the majority of reports indicate that T1D patients and age-
matched healthy controls have similar numbers of Treg cells
(Putnam et al., 2008; Brusko et al., 2007; Lindley et al., 2005).
Although freshly isolated T1D patient Treg cells have been re-
ported to be less effective suppressors than Treg cells from
healthy control donors, it was not clear from these studies
whether the Treg cells were less effective or whether the
responder Tconv cells were more resistant to suppression
(Schneider et al., 2008; Lindley et al., 2005). Importantly, Treg
cells from a T1D patient, grown ex vivo with a suboptimal
T cell expansion system incorporating rapamycin (a pharmaco-
logical inhibitor of Tconv cell responses), suppressed allogeneic
Tconv cells as potently as similarly cultured Treg cells from
healthy controls. These data suggested that functional deficits
in Treg cells from T1D patients were corrected during the expan-
sion process (Battaglia et al., 2006). This suggestion is sup-
ported by a recent study indicating that Treg cells from T1D
patients are functionally similar to those from healthy controls
and that autologous responder Tconv cells from T1D patients
are more difficult to suppress in vitro (Putnam et al., 2008).
Thus, greater insights into the biological and molecular defects
underlying given autoimmune diseases may guide the decision
to pursue immunotherapy with adoptively transferred Treg cells.
In contrast to the autoimmune response to self-antigens,
alloimmunity involves the recognition of foreign gene products
encoded by polymorphic MHC and minor histocompatibility
antigen loci. Although both the innate and adaptive immune
systems contribute to an alloresponse, the dominant effects
are mediated by allogeneic CD4+ and/or CD8+ Tconv cells,
which can directly recognize foreign MHC molecules and asso-
ciated peptides expressed on allogeneic antigen-presenting
cells (APCs) or tissue cells, or indirectly recognize foreign
peptides presented by syngeneic APCs (Rosenberg and Singer,
1992). After solid organ transplantation, alloreactivity is fueled by
inflammation and cell injury that occurs locally and is limited in
severity and duration. In contrast to hematopoietic stem cell
transplantation (HSCT), central tolerance to foreign antigens
present on transplanted solid organ grafts fails to occur. There-
fore, long-term solid organ graft acceptance requires either
continuous immune-suppressive drugs or the acquisition of
peripheral regulatory mechanisms.
After myeloablative chemoradiotherapy conditioning for
HSCT, systemic inflammation is severe and often overwhelms
immune regulatorymechanisms, despite the routine use ofmulti-agent immunosuppressive drug regimens designed to dampen
alloreactivity. Despite the more aggressive early post-HSCT
inflammatory response and the purposeful infusion of donor
T cells into a lymphopenic environment that maximally supports
their expansion, HSCT actually fosters the development of toler-
ance as host APCs are replaced with donor APCs and T cells.
Thus, the risk period for adverse donor antihost alloresponses
that culminate in the multiorgan system disorder known as
graft-versus-host disease (GVHD) typically is highest in the first
1–3 months after HSCT until central tolerance occurs. Therefore,
the critical time of need for intense immune regulation for HSCT
recipients can be precisely timed and effective immune suppres-
sion or tolerance induction during this relatively short window
may provide life-long protection against adverse alloresponses
without the need for immunosuppressive drugs. For these
reasons, and because Treg cells can be isolated from healthy
HSCT donors, human Treg cell trials in HSCT recipients have
preceded other indications.
Preclinical Data in Support for Treg Cell
Infusional Therapy in Autoimmunity
T1D results from the failure to control islet-specific Tconv cells.
The role of Treg cells in the establishment and progression of
T1D has been intensely studied. Nonobese diabetic (NOD) mice
spontaneously acquire T1D and they have been the workhorse
for murine studies of Treg cells and T1D progression (Anderson
and Bluestone, 2005). Susceptibility to diabetes correlates with
the loss of FoxP3-expressing Treg cells (Baecher-Allan and Ha-
fler, 2006). T1D can be prevented by adoptive transfer of either
freshly isolated polyclonal or antigen-specific Treg cells (Szanya
et al., 2002; Tarbell et al., 2007; Tang et al., 2004). This argues
strongly that Treg cells play a crucial role in the pathogenesis,
and potentially the treatment, of T1D. In NOD mice lacking Treg
cells, no differences in either the initial activation of Tconv cells
in draining lymph nodes or the rate of Tconv cell islet infiltration
were observed. However, accelerated islet destruction occurred
in these mice (Chen et al., 2005), suggesting that adoptive trans-
fer of functional Treg cells will be of benefit to patients with predi-
abetic lesions. Notably, 80%of IPEX patients develop T1Dwithin
a year after birth (Sakaguchi et al., 2006).
Although adoptive Treg cell therapy has been primarily
focused on T1D and HSCT, there are numerous other diseases
in which Treg cell therapy is worthy of consideration. In the afore-
mentioned study by Sakaguchi and colleagues, mice depleted of
Treg cells developed dsDNA Abs reminiscent of systemic lupus
erythematosus (SLE) (Sakaguchi et al., 1995). Others have
noticed that SLE patients have fewer Treg cells than healthy indi-
viduals, that such Treg cells are more susceptible to Fas-medi-
ated apoptosis, and that Treg cells from patients with active
disease have impaired activity (Crispin et al., 2003; Miyara
et al., 2005). Notably, ex vivo expansion of Treg cells from SLE
patients corrected the Treg cell functional defect (Valencia
et al., 2007), suggesting that ex vivo expanded, autologous
Treg cells might have a beneficial effect in SLE patients. Simi-
larly, patients with Sjo¨gren’s syndrome have reduced numbers
of Treg cells in their peripheral blood. Furthermore, SLE patients’
salivary glands, a common autoimmune target in this population,
contain markedly reduced numbers of Treg cells (Li et al., 2007).
In Sjo¨gren’s syndrome patients, Treg cells functionedImmunity 30, May 22, 2009 ª2009 Elsevier Inc. 657
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healthy controls, suggesting that Treg cell infusion has thera-
peutic potential in this disease setting (Li et al., 2007).
In other autoimmune diseases, such as multiple sclerosis
(MS), the rationale for Treg cell therapy is less clear. Results
from murine models of MS (experimental autoimmune encepha-
lomyelitis, EAE) question the therapeutic benefit of adoptive
Treg cell transfer. If polyclonal or antigen-specific Treg cells
are infused prior to acquisition of disease, EAE can be pre-
vented. However, if the Treg cells are infused after disease
initiation, their therapeutic value is considerably diminished
(Olivares-Villagomez et al., 1998). Examination of the ability of
antigen-specific Treg cells to suppress Tconv cells isolated
from the CNS of animals with active EAE revealed that Tconv
cells were highly resistant to the antiproliferative effects of
antigen-specific Treg cells, perhaps resulting from the fact that
these Tconv cells secrete high amounts of the cytokines IL-6
and TGF-b (Korn et al., 2007). There is evidence that Treg cells
function poorly in inflammatory environments (Lewis et al.,
2008). Because individuals with active autoimmune disease
like MS are likely to have inflammatory environment at or near
the target organ, pretreatment with anti-inflammatory agents
such as alpha 1-antitrypsin (Koulmanda et al., 2008; Lewis
et al., 2008) prior to infusion of ex vivo expanded Treg cells
may be of benefit. Additionally, several studies have demon-
strated that Treg cells isolated from MS patients have dimin-
ished suppressive activity (Haas et al., 2005; Viglietta et al.,
2004). If this is so, and these defects are not reversed by ex
vivo culture, it is questionable whether the infusion of additional,
presumably defective, Treg cells will provide therapeutic benefit.
Preclinical studies to determine whether autologous Treg cells
derived from progenitor cells such as gene-corrected, patient-
specific induced pluripotent stem cells derived fromMS patients
might circumvent these defects are now possible but have not
yet been performed.
Preclinical Data in Support for Treg Cell Infusional
Therapy in Alloimmunity
In cyclosporin-treated rats with long-term cardiac allograft
survival, the adoptive transfer of CD4+CD25+ T cells resulted in
tolerance (Hall et al., 1990). The demonstration that Treg cells
from naive mice prevented rejection of allogeneic skin grafts in
nude mice given CD25 Tconv cells (Sakaguchi et al., 1995)
further set the stage for the application of Treg cells to solid
organ transplant settings. In vitro studies in which positive
costimulatory pathway blockade inhibited alloantigen-specific
responsiveness demonstrated that Treg cells were essential in
the tolerance induction process as assessed in vitro and
in vivo in a GVHD model (Taylor et al., 2001). In vivo, tolerance
induced by the combined administration of donor-specific trans-
fusions and costimulatory pathway blockade was dependent
upon Treg cells present in the transfusion product (Jarvinen
et al., 2003). A series of preclinical rodent studies demonstrated
that Treg cells present in the recipient at the time of skin or
cardiac allograftingwere critical to tolerance induction andmain-
tenance in vivo (reviewed in Wood and Sakaguchi, 2003). More-
over, the adoptive transfer of CD4+CD25+ or CD4+CD45RBlo
Treg cells suppressed pancreatic islet allograft rejection (San-
chez-Fueyo et al., 2002; Davies et al., 1999).658 Immunity 30, May 22, 2009 ª2009 Elsevier Inc.In murine models, depletion of CD25+ T cells from the donor
allograft accelerated both acute and chronic rejection (Anderson
et al., 2004; Cohen et al., 2002; Hoffmann et al., 2002; Taylor
et al., 2002). Conversely, the infusion of freshly isolated or ex
vivo expanded donor Treg cells was highly effective in prevent-
ing acute or chronic GVHD (Taylor et al., 2002; Zhao et al.,
2008). Further, in vivo activated donor or host Treg cells were
able to ameliorate ongoing chronic GVHD (Anderson et al.,
2004; Zhao et al., 2008). In sublethally irradiated recipients of
T cell-depleted allogeneic bonemarrow, host antidonor alloreac-
tive Tconv cells could reject donor bone marrow, which was
preventable by donor Treg cell infusion (Joffre et al., 2004; Ha-
nash and Levy, 2005; Taylor et al., 2004). Donor Treg cell infusion
also sped immune recovery and prevented GVHD-induced
thymic involution (Trenado et al., 2003). Given the striking results
in rodent GVHD and bone marrow graft rejection models, ready
availability of donor Treg cells, known and transient risk period
for adverse consequences from alloreactive T cells, and high
degree of morbidity and mortality associated with HSCT in
patients, it is not surprising that GVHD prevention has emerged
as the first clinical application for human Treg cells.
Challenges and Clinical Applications
of Human Treg Cell Large-Scale Manufacturing
Human Treg cells have no unique cell surface markers. Trans-
lating Treg cells into the clinic has been hindered by the relatively
high frequency of activated Tconv cells present in the
CD4+CD25+ fraction and the limited availability of good
manufacturing practice (GMP)-compatible procedures for
removing these contaminants. Furthermore, the relatively low
frequency of Treg cells in human peripheral blood, combined
with data frommousemodels indicating that large doses of poly-
clonally activated Treg cells are required to suppress GVHD,
indicate that for most applications, Treg cells will require ex
vivo expansion. Expansion approaches that provide strong
TCR signals tend to preferentially expand Tconv cells at the
expense of Treg cells. Thus, it is essential to either initiate the
expansion culture with highly purified Treg cells or create culture
conditions that favor Treg cell outgrowth. Most preclinical
human data analyzing human Treg cells have been generated
with research-grade materials and antibody-coated magnetic
beads or high-speed cell sorting. As such, these approaches
have proven insufficiently robust for exportation to most institu-
tions for Treg cell isolation under GMP conditions because of the
unavailability of equivalent GMP reagents and paucity of GMP-
compliant cell sorters.
The FDA mandates that the sterility, identity, purity, and
potency of a cell therapy product be demonstrated before
administration to patients. Sterility is the most straightforward
quality to demonstrate, because assays performed on Tconv
cell populations can be directly translated to Treg cells. Likewise,
tracking measures, such as HLA verification and barcoding of
reagents and plastics that come in contact with a particular
cell product, employed to establish identity of one patient’s
cell product as it moves through the various processing, expan-
sion, and validation steps prior to being reinfused require no
adaptation for use in Treg cells. However, demonstrations of
Treg cell purity and potency are more problematic. Foxp3
expression is a good surrogate for Treg cell purity, but given
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will be 100% Foxp3+ after expansion. It will be important to
determine ‘‘acceptable’’ amounts of contamination, from both
quantitative and qualitative perspectives, which may be disease
dependent. For reasonably well-controlled autoimmune
diseases such as T1D, the acceptable proportion of non-Foxp3-
expressing cells will be lower than the acceptable proportion of
non-Foxp3-expressing cells in acute GVHD therapy that is
a severe multiorgan system disease caused by high numbers
of Tconv cells. From the qualitative perspective, it is possible,
for example, that contaminating naive Tconv cells will be less
problematic in autoimmune disease applications because it is
unlikely that the pathogenic Tconv cells are in this subset,
whereas contaminating memory cells may be less problematic
in GVHD or organ transplant situations, because the alloreactive
response is more likely to be contained in the naive T cell reper-
toire. Given these issues, it is unknown whether culture condi-
tions capable of skewing the contaminating repertoire can be
developed, especially under GMP-imposed constraints.
Monitoring of potency clearly separates Treg cells from other
T cell-based therapies. For Tconv cell therapy there are in vitro
surrogates, such as polyfunctional cytokine secretion by CD4+
T cells and lytic potential of CD8+ T cells that correlate well
with in vivo efficacy (Betts et al., 2006). Unfortunately, our under-
standing of Treg cell function lags considerably behind our
understanding of Tconv cell function. Multiple mechanisms
have been implicated in Treg cell function, but there is no clear
understanding of how suppression occurs in vivo (Tang and
Bluestone, 2008). Although most investigators use the ability of
Treg cells to inhibit T cell proliferation as a primary endpoint of
in vitro suppression assays, there are many ways to measure
this outcome. Suppression in some of the assays is lost when
exogenous cytokines such as IL-2 are added, whereas others
show suppression in the presence of IL-2. Some but not other
assays are APC dependent so that if the Treg cells are acting
upon APCs, suppression will be observed (Shevach, 2009, in
this issue of Immunity). Moreover, the correlation between
in vivo Treg cell activity and activity measured in vitro assays is
not perfect. We recently reported that CD4+ Tconv cells
expanded in the presence of rapamycin were highly effective in
an in vitro suppression assay, but these cells failed to function
in an in vivo xeno-GVHD model (Golovina et al., 2008). Along
the same lines, it is reasonable to conclude that Treg cells
suppress GVHD and autoimmune disease by similar mecha-
nisms, but this has not been formally demonstrated. Does this
mean that investigators must develop disease-specific models
to test the potency of expanded Treg cell products? Recent
advances in tissue engineering (Azuma et al., 2007) and
immune-deficient mousemodels (Shultz et al., 2007; von Herrath
andNepom, 2009) havemade it possible to use human Treg cells
to prevent antihuman immune responses, but these models are
just becoming established and their ability to predict human
therapy is unproven. Considerable work is required to generate
and validate fully human models of T1D, lupus, and organ trans-
plantation.
Many of the reagents and approaches used in clinical expan-
sion of human Treg cells can also be used with nonhuman
primates (Haanstra et al., 2008; Ansari et al., 2007). Given that
nonhuman primates have been instrumental in improving andvalidating organ transplant protocols (Lechler et al., 2005), it
would seem likely that transplant studies in nonhuman primates
would guide the in vivo use of human Treg cells. However, it is
important to note that nonhuman primate models were used
in the evaluation of the superagonistic anti-CD28 Ab TGN1412
and no toxicities were observed, calling into question the uniform
utility of nonhuman primate models for Treg cell therapy
(Schraven and Kalinke, 2008). Understanding when nonhuman
primate studies will be informative and appropriate will be useful
in driving the clinical translation of ex vivo expanded Treg cells
for some indications. In any case, during the developmental
stages of Treg cell therapy, there is an urgent need for in vivo-
validated in vitro Treg cell functional assays so that the quality
of expanded Treg cell cultures can be quickly and accurately
assessed.
Current Phase I Clinical Trials Evaluating Adoptively
Transferred Treg Cells
Allogeneic Treg cells have been infused into HSCT recipients in
Germany and the US. These studies both utilized antibody-
coated magnetic-bead separation techniques to first deplete
non-T cells (B cells ±monocytes; NK cells), followed by a positive
selection step to enrich for CD25+ cells via a subsaturating
concentration of CD25 antibody to capture the CD25hi fraction
(Figure 1; Godfrey et al., 2004, 2005). The final isolation products
contained 50% Treg cells as assessed by CD4, CD25, and
FoxP3 flow cytometry. Further enrichment based upon FoxP3
expression is not possible because FoxP3 detection requires
permeabilization. By eliminating the ex vivo expansion step,
Edinger and coworkers initiated a trial in which freshly isolated
allogeneic donor Treg cells are infused, avoiding the preferential
expansion of contaminating Tconv cells (M. Edinger, personal
communication). These fresh Treg cells were administered in
a post-transplant setting to HSCT recipients who also were given
a donor lymphocyte infusion to prevent or treat recurrent hema-
tological malignancies. In concurrent phase I dose escalation
trials at the University of Minnesota conducted by the coauthors
and their colleagues, umbilical cord blood (UCB) was used for
Treg cell isolation because cord blood is virtually devoid of
memory T cells (Figure 1). In ongoing trials, nonmyeloablated
or myeloablated recipients of two unrelated UCB units used for
hematopoietic reconstitution, given with standard of care
GVHD prophylactic pharmacological agents (cyclosporine A;
mycophenolate mofetil), also received third-party, HLA partially
matched Treg cells. Although CD25hi Treg cells are more
readily purified from umbilical cord blood than from peripheral
blood (Godfrey et al., 2004, 2005), only 5–7.5 3 106 Treg cells
can be isolated from a frozen UCB unit. Thus, to achieve high
Treg cell:Tconv cell ratios, cord blood Treg cells used in this
study were expanded with anti-CD3 and anti-CD28-coated
microbeads and IL-2, resulting in 200- to 300-fold expansion
in %3 weeks. The ability to expand peripheral blood Treg
cells was advanced by the discovery that the immunosuppres-
sant rapamycin selectively expands or preferentially pre-
serves Treg cells over Tconv cells (Battaglia et al., 2005)
because of the FoxP3-induced expression of Pim2, a serine-
threonine kinase that confers rapamycin resistance (Basu
et al., 2008). However, it should be noted that Treg cells are
not immune to the effects of rapamycin—just less affectedImmunity 30, May 22, 2009 ª2009 Elsevier Inc. 659
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As a source of peripheral blood Treg cells, a nonmobilized apheresis unit is obtained from the HSCT donor 18–20 days prior to transplant (left). Non-Treg cell
populations are depleted of CD8, CD14, and CD19 with either magnetic beads or flow cytometry techniques. Alternatively, a third-party UCB unit is used that
does not require negative selection (right). Treg cells are enriched by CD25-positive selection. These populations can be expanded with CD3 and CD28
mAb-coatedmicrobeads or a cell-based aAPC consisting of K562 cells transduced to express CD86 and an FcR (CD32 or CD64) uponwhich CD3mAb is loaded.
Exogenous IL-2, rapamycin, and an irradiated CD4+CD25 feeder layer were added to the culture for peripheral blood Treg cell expansion, whereas UCBTreg cell
expansion required only supplemental IL-2. After quality control studies are completed, Treg cells are infused in the peri-HSCT period either in the context of
GVHD prophylactic drugs or T cell mAb or in vitro T cell depletion. The approximate cell yields at each step are listed.than Tconv cells. Thus, multiple ex vivo stimulations may be
required to achieve therapeutic doses of Treg cells (Golovina
et al., 2008).
As noted above, UCB Treg cells are an attractive therapeutic
modality. They are largely naive, have long telomeres, and are
easily separated from Tconv cells because of the reduced
complexity of UCB T cell subsets. One drawback is that to date
UCB has been employed as an allogeneic cell source, necessi-
tating HLA matching and opening the possibility of host versus
graft or graft versushostdisease.However,within the last decade
or so, banking of infant UCB has increased markedly, so it is
possible to envision autologous UCB therapy and in particular,
therapy with ex vivo expanded autologous UCB-derived Treg
cells. Investigators at the University of Florida (Haller, Atkinson,
and Schatz) have infused 23 T1D individuals with autologous,
unfractionated UCB (M.A. Atkinson, personal communication).
Because UCB contains mesenchymal stem cells, Treg cells,
and perhaps other undefined cells with suppressor activity, it
will be difficult to ascribe any therapeutic benefit to a particular
cell subset. Nonetheless, this trial establishes the safety, and
rather impressively, the feasibility of using autologous UCB to
treat autoimmune disease, opening many exciting possibilities
for future trials. Thus, it is possible to envision future approaches
with similar advantages of UCB with autologous Treg cells
derived from induced pluripotent stem cells.660 Immunity 30, May 22, 2009 ª2009 Elsevier Inc.Potential Dangers of Human Treg Cell Therapy
Like all therapies, clinical use of ex vivo expanded Treg cells is
associated with potential risks. Perhaps the most troublesome
is the possibility of expanded Treg cells reverting to Tconv cells,
especially if antigen-specific Treg cells are infused. The notion of
plasticity among the various T cell subsets has gained much
attention (Zhou et al., 2009, in this issue of Immunity), driven in
part by studies with Foxp3EGFP knockin mice (Fontenot et al.,
2005). One surprising and intriguing finding from this line of
research is that TGF-b is required for both Treg and Th17 cell
differentiation, with the ultimate fate decision resting on interac-
tions between the transcription factors SMAD4, RORg, RORa,
STAT3, and the cytokines IL-1 and IL-6 (Yang et al., 2008; Rad-
hakrishnan et al., 2008). The majority of adoptively transferred
Treg cells maintain their suppressive activity, but a minority of
cells lose Foxp3 expression and can differentiate into Tconv cells
(Komatsu et al., 2009). Understanding why cells lose their ‘‘Treg-
ness’’ and preventing this dedifferentation in vivo will improve
both the safety and efficacy of Treg cell therapy. Because
Foxp3 is the master regulator of Treg cell function (Josefowicz
and Rudensky, 2009, in this issue of Immunity), alterations in
Foxp3 expression or activity are likely involved in converting
Treg cells to Tconv cells. Foxp3 expression is modulated by
DNA methylation via CpG islands in its promoter (Kim and Leo-
nard, 2007) and by chromatin remodeling (Tao et al., 2007).
Immunity
ReviewTherefore, administration of selective demethylation agents and/
or histone protein deacetylases (HDACs) may enhance Treg cell
function and fidelity in vivo. It will be of interest to determine
whether human Treg cells are as plastic as their murine counter-
parts when given in vivo for therapeutic intent.
There are also concerns that excessive Treg cell activity may
blunt the response to infectious agents or lead to higher rates
of tumor occurrence or relapse. These are justified concerns.
However, one study showed that augmenting Treg cell activity
via TGF-b administration protected NOD mice from T1D but
did not prevent coxsackievirus clearance (Richer et al., 2008).
Clearly, more studies are required to examine whether thera-
peutic levels of adoptively transferred Treg cells restrict protec-
tive immune responses. Although the use of suicide vectors may
be an attractive way to eliminate introduced Treg cells if exces-
sive immunosuppression is observed, this would likely require
some form of gene therapy, which requires its own careful
assessment of risks and rewards.
Future Directions for Treg Cells in the Clinic
Treg cells are not a homogeneous population. Like their Tconv
cell counterparts, they can be divided into subsets based on
differential cell surface marker expression (Gajewski, 2007).
The functional implications of these differences are now
becoming apparent. For example, ICOS+ Foxp3+ Treg cells
produce more IL-10 than do their ICOS Foxp3+ counterparts
and it has been suggested that they play a more important role
in modulating dendritic cell function (Ito et al., 2008). Most adop-
tive T cell therapy studies to date have used CD4+CD252+ or
CD4+CD25+CD127 cells, but now that it is clear that human
Treg cell subsets exist, it is essential to determine whether one
particular subset(s) is more attractive for therapeutic use. It is
possible that Treg cell subset appropriateness will vary with
the application. Perhaps distinct Treg cell subsets will be best
suited for GVHD applications, whereas other subsets may be
better suited to control autoimmune diseases, perhaps depen-
dent upon trafficking patterns or relative survival in a particular
niche. Understanding how chemokines and integrins (Wei
et al., 2006) control the migration and perhaps survival of distinct
Treg cell subsets will enable informed decisions concerning
which, if any, Treg cell subset to employ for a particular clinical
application.
After antigen encounter, a subset of naiveTconvcells becomes
memory T cells. Do memory Treg cells exist, and if so, would
these antigen-experienced cells respondmore rapidly and vigor-
ously to antigen? A study examining MS patients revealed that
the number of CD31+ cells coexpressing CD4, CD25, CD45RA,
and Foxp3 declines with age in healthy controls and this decline
is more severe in MS patients (Haas et al., 2007). Although these
data suggest that maintaining a pool of naive Treg cells is impor-
tant, it is important to note that theexistenceof Tregmemorycells
has not been demonstrated. Because Treg cells appear to retain
expression of CCR7, CD62L, CD28, and CD27, but do not
express CD127 (Liu et al., 2006; Hoffmann et al., 2006; Godfrey
et al., 2005), it is unclear how Treg memory cell subsets can
best be defined phenotypically. Both CD45RA+CD252+ and
CD45RO+CD252+ Treg cells exist, but it is not clear whether
the CD45RO cells represent contaminating Tconv or Treg cells.
In any case, CD45RO+CD252+ cells exhibited significantly lesssuppressive activity after expansion than did CD45RA+CD252+
cells (Hoffmann et al., 2006), suggesting that these cells do
not have the functional properties of memory Treg cells.
As evident from our title, it is unclear what constitutes a thera-
peutic dose of Treg cells. The answer depends on many factors,
including the specific disease targeted and whether polyclonal
or antigen-specific Treg cells are employed. Defining Treg cell
dosing strategies requires large-scale Treg cell expansion
capacity. It has been reported that with a murine cell-based
artificial APC (aAPC) system, human Treg cells could be
expanded 40,000-fold in 3–4 weeks (Hoffmann et al., 2004).
Unfortunately, this study preceded the development of robust
Foxp3 staining protocols and in vivomodels of Treg cell function,
so the purity and potency of these Treg cells is difficult to ascer-
tain. Subsequent studies have reported more modest expansion
of Treg cells with anti-CD3- and anti-CD28-coated beads (of
which GMP versions are available) in the presence of high
amounts of IL-2 (Earle et al., 2005; Godfrey et al., 2004). We
have found that anti-CD3 Ab-loaded K562-based aAPCs expand
Treg cellsmore efficiently, and the expanded cells exhibit greater
purity and potency than do cells expanded with anti-CD3 and
anti-CD28 beads (Golovina et al., 2008; Hippen et al., 2008).
Moreover, when using these aAPCs, a 1000-fold expansion in
3weeks is achievable if two stimulations are employed,making
it feasible to propose dosing at numbers comparable to those
used in CD4+ Tconv cell adoptive transfer applications. Another
advantage of K562-based aAPCs is that additional cell surface
(costimulatory molecules) and secreted (cytokines and chemo-
kines) molecules can be easily added to further refine human
Treg cell expansion (Suhoski et al., 2007). To date, our data
with human isolated from peripheral blood indicate that addition
of costimulatory ligands other than CD86 favors the expansion of
contaminating Tconv cells at the expense of Treg cells (Golovina
et al., 2008). In contrast, expansion of UCB Treg cells can be
enhanced by the presence of additional costimulatory ligands
(Hippen et al., 2008). This discrepancy is most likely a conse-
quence of the substantially higher purity of the starting Treg
cell populations from UCB. Lastly, because K562 cells are of
human origin, and irradiated K562 variants expressing GM-
CSF have been safely injected into humans (Nemunaitis et al.,
2006), this raises the possibility of in vivo Treg cell expansion
with irradiated K562-based aAPCs.
The ability to overcome some of the limitations of Treg cell
therapy by genetically reprogramming Treg cells is potentially
attractive, especially in light of the availability of clinical grade len-
tiviral vectors (Levine et al., 2006). One area of active research is
to use vectors to redirect polyclonal Treg cells to specific targets.
In murine models of T1D, antigen-specific Treg cells are far more
potent than polyclonal Treg cells on a per-cell basis (Tang et al.,
2004). However, current technology does not easily permit the
identification of islet-specific Treg cells in humans. Moreover,
multiple rounds of expansion would likely be required to obtain
therapeutic numbers of Treg cells, whichmight compromise their
engraftment, persistence, or function. In murine models, intro-
duction of a chimeric immune receptor (CIR) into Treg cells pre-
vented experimental autoimmune encephalomyelitis (Mekala
and Geiger, 2005) and experimental-induced colitis (Eran et al.,
2009). Likewise, recent advances in engineering and expressing
TCRs that redirect T cell specificity (June, 2007) could also beImmunity 30, May 22, 2009 ª2009 Elsevier Inc. 661
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2002). We recently demonstrated that high-affinity TCRs
conferred greater effector function to Tconv cells (Varela-Rohena
et al., 2008). It will be interesting to determinewhether this applies
to Treg cells as well. Additional gene modifications can be envi-
sioned that may enhance the therapeutic potential of Treg cells.
The FoxP3 deficiency in IPEX patients could be corrected in
T cells, or even better in hematopoietic stem cells, by either
zinc-finger nuclease-mediated repair for a pointmutation or small
insertions/deletions (Urnov et al., 2005) or lentiviral vector-medi-
ated introductionof thewild-typeFoxp3geneunder thecontrol of
a Treg cell-specific promoter. Likewise, to prevent the Treg-
Tconv cell conversion, Treg cells could be engineered to consti-
tutively overexpress Foxp3 so that these infused Treg cells are
less likely to convert to Tconv cells. Lastly, as our knowledge of
Treg cell immune-suppressivemechanisms increases, additional
opportunities to enhance Treg cell function via gene therapy will
present themselves.
Because natural Treg cells are present at a low frequency in
peripheral blood, CD25-based purification techniques remove
the vast majority of CD4+ T cells. Because CD4+CD25 T cells
can be induced to express high amounts of FoxP3, an alternative
approach to natural Treg cell purification is to generate inducible
Treg cells (iTreg cells) by subjecting CD4+CD25 T cells to condi-
tions that result in the gain of suppressor cell function (Curotto de
Lafaille and Lafaille, 2009, in this issue of Immunity). Although
some species-specific differences are likely to exist,murine iTreg
cells can be generated after ex vivo exposure of naive
CD4+CD25 or CD4+CD45RO T cells to TGF-b (Chen et al.,
2003), especially in the presence of IL-2 or IL-10, vitamin D3 (Bar-
rat et al., 2002), all trans-retinoic acid (Benson et al., 2007), indo-
leamine 2,3 dioxygenase (Chen et al., 2008), or FoxP3-express-
ing retroviruses (Hori et al., 2003). Other strategies for in vitro
iTreg cell generation may include exposing CD4+CD25 T cells
to subimmunogenic antigen-loaded dendritic cells or to histone
deacetylase inhibitors that specifically regulate FoxP3 expres-
sion. Although potentially promising, there is a paucity of data
regarding the yield, stability, plasticity, and relative potency of
iTreg versus natural Treg cells as assessed by both in vitro and
in vivo measures. Thus, it would be premature to gauge whether
iTreg cell generation may circumvent the technical limitations of
producing high numbers of natural Treg cells via GMP reagents.
Concluding Statements
It is becoming increasingly clear that a major component of the
next wave of therapeutic agents that will attempt to tackle our
unmet medical needs will be cell and gene therapy. When this
wave will hit the clinics and become the standard of care for
many disease states is far away, but we are convinced that it
will happen because cells and in particular Treg cells offer the
ability to be highly specific and strikingly effective. Also, Treg
cell therapy has the promise of avoiding many of the toxicities
observed with current drug regimens. An argument can be
made that this potential was realized perhaps too early, before
we really had a reasonable understanding of the checks and
balances the immune system employs to maintain tolerance
and promote immunity. Many of the initial attempts at Treg cell
therapy used inferior cell expansion systems that did not
produce cells with a high engraftment potential, and many of662 Immunity 30, May 22, 2009 ª2009 Elsevier Inc.the gene therapy products proved to be highly immunogenic
and were rapidly cleared from the body. We are now poised to
enter the next generation of cell and gene therapy, armed with
volumes of basic research and preclinical testing. Will this infor-
mation be sufficient to unlock the power of Treg cells and provide
better options for those suffering from autoimmune and other
immune-mediated disease states? Only time and hard work
will answer this question but nonetheless we envision that one
day, as our title implies, Treg cell therapy will be as common-
place as taking two aspirins.
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